Skin Cancer News and Research

Latest Skin Cancer News and Research

AAD SEAL OF RECOGNITION program to be phased out

The American Academy of Dermatology (AAD) has decided to phase out its AAD SEAL OF RECOGNITION(R) program over the next two years, and will cease accepting new applications effective immediately. Products which were accepted into the program prior to November 15, 2009, will continue to carry the AAD SEAL OF RECOGNITION(R) until the end of their two-year terms.

3 Dec 2009

High-frequency ultrasound with elastography improves skin cancer diagnosis

High-frequency ultrasound with elastography can help differentiate between cancerous and benign skin conditions, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

1 Dec 2009

Presentations at Tuesday's RSNA conference

A new study from Cincinnati Children's Hospital Medical Center reports that beverage can stay-tabs pose a potential ingestion risk. In the 1970s, U.S. manufacturers switched to the stay-tab design after safety concerns about pull-tabs. The new study found 19 cases of stay-tab ingestion at a single institution, mainly among teenagers.

30 Nov 2009

Charity urges government to stop under 18s from using sunbeds

Tomorrow Scotland takes steps to protect children from sunbeds by banning under 18s from using them and ensuring adults are fully informed of the risks, Cancer Research UK wants Westminster to bring the rest of the UK up to Scottish standards.

30 Nov 2009

Researchers develop new device to detect skin cancer

Researchers at Ben-Gurion University of the Negev are developing a new device that detects cancerous skin tumors, including melanomas that aren't visible to the naked eye.

25 Nov 2009

People with severe EBS at increased risk of skin cancer, say scientists

UK scientists have discovered the link between people with the skin blistering disease Epidermolysis Bullosa Simplex-Dowling-Meara, (EBS -DM) - and tumour growth, according to research published in Journal of Investigative Dermatology today (Monday).

25 Nov 2009

Delcath Systems sponsors "Regional Therapeutic Options for Metastatic Melanoma" symposium

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, recently sponsored a Satellite Symposium at the World Meeting of Melanoma/Skin Cancer Centers in Berlin, Germany. The session, titled "Regional Therapeutic Options for Metastatic Melanoma," was held on Friday, November 20 and featured updates and observations on a variety of current therapies by clinical leaders in the field.

24 Nov 2009

BioAlliance Pharma's AMEP biotherapy reduces both tumour growth and tumour angiogenesis

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented preclinical results on its new biotherapy, AMEP™ for advanced and metastatic melanoma at the ESGCT (European Society of Gene and Cell Therapy) in Hannover (November 21 to 25, 2009).

24 Nov 2009

Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that initial one year overall survival data from the first 20 subjects in the current Phase 2 trial showed comparable trends to Phase 1 survival data.

23 Nov 2009

Genes from same 'family' interact with each other to prevent skin cancer, says new study

CANCER RESEARCH UK scientists have shown, for the first time, how two genes from the same 'family' can interact with each other to stop cancer in its tracks - according to new findings published in Molecular Cell.

23 Nov 2009

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company’s lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion.

20 Nov 2009

Low-level laser therapy increases tumour growth in skin cancer

High irradiances of low-level laser therapy (LLLT) should not be used over melanomas. Researchers writing in the open access journal BMC Cancer studied the pain relieving, anti-inflammatory 'cold laser', finding that it caused increased tumour growth in a mouse model of skin cancer.

19 Nov 2009

Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany.

17 Nov 2009

Peplin merges with LEO Pharma

Peplin, Inc. today announced that it has completed its merger with LEO Pharma A/S (LEO) after obtaining the approval of the majority of Peplin stockholders. The deal was originally announced on 3 September, 2009 when LEO, a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, agreed to acquire all outstanding securities of Peplin for approximately US$287.5 million in cash. The merger consideration will be distributed to holders of common stock and CDIs promptly.

13 Nov 2009

Tips for preventing cancer

The risk of cancer can be dramatically reduced through everyday choices about diet, exercise and tobacco use, according to a Special Report on Cancer Prevention in the November issue of Mayo Clinic Women's HealthSource.

12 Nov 2009

Common myths about sun exposure, sunscreen and vitamin D

When it comes to vitamin D, consumers are bombarded with mixed messages about the best source for this essential nutrient. While some may argue that small doses of intentional sun exposure are safe, dermatologists point out that the risk of developing skin cancer from ultraviolet (UV) radiation far outweighs the benefit of stimulating vitamin D production - particularly when enriched foods and supplements are safe and effective sources of this vitamin.

11 Nov 2009

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer.

10 Nov 2009

New technique to identify patients more likely to survive advanced melanoma

Although the chances of surviving advanced melanoma aren't very good with current therapies, some patients can live for years with cancer that has spread beyond the skin to other organs. Now it may be possible to identify which patients are more likely to survive by analyzing the activity of hundreds of genes involved in the immune response and gene proliferation, according to researchers at NYU Langone Medical Center.

10 Nov 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.

5 Nov 2009

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival, according to data presented on Tuesday, November 3, 2009 at the 51st American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Chicago, Illinois.

4 Nov 2009

Skin Cancer News and Research

Latest Skin Cancer News and Research

AAD SEAL OF RECOGNITION program to be phased out

High-frequency ultrasound with elastography improves skin cancer diagnosis

Presentations at Tuesday's RSNA conference

Charity urges government to stop under 18s from using sunbeds

Researchers develop new device to detect skin cancer

People with severe EBS at increased risk of skin cancer, say scientists

Delcath Systems sponsors "Regional Therapeutic Options for Metastatic Melanoma" symposium

BioAlliance Pharma's AMEP biotherapy reduces both tumour growth and tumour angiogenesis

Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma

Genes from same 'family' interact with each other to prevent skin cancer, says new study

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Low-level laser therapy increases tumour growth in skin cancer

Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma

Peplin merges with LEO Pharma

Tips for preventing cancer

Common myths about sun exposure, sunscreen and vitamin D

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

New technique to identify patients more likely to survive advanced melanoma

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Skin Cancer News and Research

Latest Skin Cancer News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in